Leidos (LDOS) Faces DHA Move To Replace It On Military Health Records

June 18, 2026 - 00:41

The Defense Health Agency is planning to replace Leidos Holdings as the lead systems integrator for the Military Health System's electronic health record program. This decision directly impacts the company's role in the multi-year MHS GENESIS rollout across U.S. military treatment facilities.

The move introduces significant uncertainty for Leidos' health segment and its standing in the federal health IT market. MHS GENESIS is a major initiative designed to modernize medical record-keeping for active duty personnel, veterans, and their families. Losing the lead integrator role would represent a substantial shift in the company's revenue stream from government contracts.

Analysts have responded by issuing downgrades on the stock, citing concerns about profit margins and organic growth tied to this contract. The potential loss raises questions about Leidos' ability to maintain its competitive edge in the defense and health technology sectors. While the company has diversified operations, the health records program has been a cornerstone of its federal business.

The Defense Health Agency has not provided a detailed timeline for the transition. For now, Leidos continues to support ongoing deployments, but the long-term outlook for its health IT division remains clouded by the agency's plans.